# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Joel Beatty initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Outperform rating and announces Price Tar...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $35 price t...
https://www.marijuanamoment.net/top-federal-drug-official-says-theres-tremendous-excitement-around-psych
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
Regarding Hertz, Jim Cramer said, "I don't want you to sell, and I don't want you to double down. Let's just se...
Oppenheimer analyst Francois Brisebois reiterates Mind Medicine (NASDAQ:MNMD) with a Outperform and lowers the price target ...
HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price targe...
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undia...